{"filing":{"accession_number":"0001213900-26-064294","cik":"0001845459","ticker":null,"company_name":"NKGen Biotech, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"ea0292593-8k_nkgen.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/ea0292593-8k_nkgen.htm"},"events":[{"id":7528,"run_id":6615,"accession_number":"0001213900-26-064294","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"NKGen Biotech entered into a Third Amendment to its Secured Convertible Loan Agreement on May 27, 2026, receiving $2.2 million in net proceeds through an unregistered sale of equity securities including a convertible promissory note (Additional Note #3) convertible at $0.08 per share, warrants exercisable at the same price, and 12,953,947 consideration shares to be delivered over 30 months. The transaction creates substantial dilution to existing shareholders through conversion, warrant exercise, and direct share issuance, typical of cash-strapped biotech financing.","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3657,"accession_number":"0001213900-26-064294","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"NKGen Biotech entered into a Third Amendment to its Secured Convertible Loan Agreement on May 27, 2026, receiving an additional $2.2 million in net proceeds. The transaction involves issuance of a convertible promissory note (Additional Note #3) convertible at $0.08 per share, warrants exercisable at the same price, and 12,953,947 consideration shares to be delivered over 30 months. The cumulative dilution from conversion and warrant exercise, combined with the voting agreement requiring stockholder approval to increase authorized shares, signals a highly dilutive financing typical of cash-strapped biotech companies. While this could also be classified as ma_activity (material definitive agreement), the core economic substance is a dilutive equity issuance to raise capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:19.105563+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3658,"accession_number":"0001213900-26-064294","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control transaction that creates a direct financial obligation. The cross-reference structure is typical of M\u0026A activity disclosures where the transaction details appear in Item 1.01 and financial obligations are summarized in Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:19.105563+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3659,"accession_number":"0001213900-26-064294","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NKGen Biotech disclosed an unregistered sale of equity securities under Item 3.02, including consideration shares issued in installments, a convertible note (Additional Note #3), and a warrant (Additional Warrant #3), all issued without Securities Act registration and relying on Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This is a classic dilutive private placement that would materially affect shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:19.105563+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3657,"accession_number":"0001213900-26-064294","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"NKGen Biotech entered into a Third Amendment to its Secured Convertible Loan Agreement on May 27, 2026, receiving an additional $2.2 million in net proceeds. The transaction involves issuance of a convertible promissory note (Additional Note #3) convertible at $0.08 per share, warrants exercisable at the same price, and 12,953,947 consideration shares to be delivered over 30 months. The cumulative dilution from conversion and warrant exercise, combined with the voting agreement requiring stockholder approval to increase authorized shares, signals a highly dilutive financing typical of cash-strapped biotech companies. While this could also be classified as ma_activity (material definitive agreement), the core economic substance is a dilutive equity issuance to raise capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:19.105563+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-06-02"},{"id":3658,"accession_number":"0001213900-26-064294","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control transaction that creates a direct financial obligation. The cross-reference structure is typical of M\u0026A activity disclosures where the transaction details appear in Item 1.01 and financial obligations are summarized in Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:19.105563+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-06-02"},{"id":3659,"accession_number":"0001213900-26-064294","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NKGen Biotech disclosed an unregistered sale of equity securities under Item 3.02, including consideration shares issued in installments, a convertible note (Additional Note #3), and a warrant (Additional Warrant #3), all issued without Securities Act registration and relying on Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This is a classic dilutive private placement that would materially affect shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:19.105563+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-06-02"}]}